<div id="readability-page-1"><p><span>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report)</span> had its price target boosted by investment analysts at Citizens Jmp  from $35.00 to $57.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a &#34;market outperform&#34; rating on the stock. Citizens Jmp's price target suggests a potential upside of 27.77% from the company's previous close.</p><div><p><span></span><span>Get <strong>Terns Pharmaceuticals</strong> alerts:</span></p></div><p>Several other brokerages also recently commented on TERN. Truist Financial boosted their target price on Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday. Mizuho upped their price objective on shares of Terns Pharmaceuticals from $33.00 to $54.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday. HC Wainwright raised their target price on shares of Terns Pharmaceuticals from $20.00 to $60.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday. Barclays boosted their target price on shares of Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday. Finally, William Blair upgraded Terns Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research report on Monday, November 3rd. One investment analyst  has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat.com, Terns Pharmaceuticals  has an average rating of &#34;Moderate Buy&#34; and an average target price of $55.56.</p><p><b>View Our Latest Report on TERN</b></p><h2>Terns Pharmaceuticals Price Performance</h2><p>NASDAQ TERN opened at $44.61 on Thursday. The business has a fifty day moving average price of $18.21 and a two-hundred day moving average price of $10.03. The stock has a market capitalization of $4.02 billion, a PE ratio of -43.31 and a beta of -0.24. Terns Pharmaceuticals has a fifty-two week low of $1.87 and a fifty-two week high of $48.26. </p><p>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.03.  As a group, sell-side analysts expect that  Terns Pharmaceuticals will post -1.19 earnings per share for the current year. </p><h2>Insider Transactions at Terns Pharmaceuticals</h2><p>In other Terns Pharmaceuticals news, Director Jill M. Quigley sold 24,520 shares of the business's stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $18.00, for a total transaction of $441,360.00. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Company insiders own  1.50% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds have recently modified their holdings of the stock. Engineers Gate Manager LP bought a new stake in  Terns Pharmaceuticals during the second quarter worth $41,000.  Canada Pension Plan Investment Board bought a new position in  Terns Pharmaceuticals during the 2nd quarter valued at $46,000.  LeConte Wealth Management LLC purchased a new position in  Terns Pharmaceuticals during the 2nd quarter worth $47,000.  Dynamic Technology Lab Private Ltd bought a new stake in shares of  Terns Pharmaceuticals in the 1st quarter worth $51,000.  Finally, Velan Capital Investment Management LP grew its stake in shares of  Terns Pharmaceuticals by 17.6% in the 2nd quarter. Velan Capital Investment Management LP now owns 20,000 shares of the company's stock worth $75,000 after acquiring an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own  98.26% of the company's stock. </p><h2>About Terns Pharmaceuticals</h2> (Get Free Report)<p>Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Terns Pharmaceuticals</li><li>How to Start Investing in Real Estate</li><li>Walmart’s NASDAQ Switch Could Change Everything for WMT Stock</li><li>Are Penny Stocks a Good Fit for Your Portfolio?</li><li>GameStop Looks Broken: Here’s Why GME Could Crash in 2026</li><li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li><li>Market Momentum: 3 Stocks Poised for Major Breakouts</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Terns Pharmaceuticals Right Now?</h2><p>Before you consider Terns Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.</p><p>While Terns Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TERN

<p>Citizens Jmp raised Terns Pharmaceuticals' price target from $35.00 to $57.00, giving it a "market outperform" rating. Other firms also increased their targets, with Truist Financial, Mizuho, HC Wainwright, and Barclays boosting their price objectives. The stock opened at $44.61 on Thursday, with a market cap of $4.02 billion. Analysts expect Terns Pharmaceuticals to post -1.19 EPS for the year. Institutional investors own 98.26% of the stock.</p>

Terns Pharmaceuticals (NASDAQ:TERN) Price Target Raised to $57.00